Engelsk

Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.

5 Formulär  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    4. Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    5. Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
pht005602
Beskrivning

pht005602

Alias
UMLS CUI [1,1]
C3846158
De-identified sample ID
Beskrivning

SAMPLE_ID

Datatyp

string

Alias
UMLS CUI [1,1]
C4684638
UMLS CUI [1,2]
C1299222
Body site where sample was collected [Blood, bone, liver, lung, lymph node, Prostate Bed, Soft Tissue, supraclavicular aden
Beskrivning

BODY_SITE

Datatyp

string

Alias
UMLS CUI [1,1]
C0449705
Analyte type [DNA, RNA]
Beskrivning

ANALYTE_TYPE

Datatyp

string

Alias
UMLS CUI [1,1]
C4744818
Tumor status [metastatic tumor, normal]
Beskrivning

IS_TUMOR

Datatyp

string

Alias
UMLS CUI [1,1]
C0475752
Primary metastatic tumor
Beskrivning

PRIMARY_METASTATIC_TUMOR

Datatyp

text

Alias
UMLS CUI [1,1]
C0677930
UMLS CUI [1,2]
C0027627
Primary tumor location
Beskrivning

PRIMARY_TUMOR_LOCATION

Datatyp

text

Alias
UMLS CUI [1,1]
C0475447
Stage
Beskrivning

Stage

Datatyp

text

Alias
UMLS CUI [1,1]
C1300072
Tumor treatment
Beskrivning

TUMOR_TREATMENT

Datatyp

text

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0027651
Treatment post visit
Beskrivning

TREATMENT_POST_VISIT

Datatyp

text

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0231290
UMLS CUI [1,3]
C0545082
Cell or tissue type or subtype of sample
Beskrivning

HISTOLOGICAL_TYPE

Datatyp

string

Alias
UMLS CUI [1,1]
C2347026
UMLS CUI [1,2]
C0007634
UMLS CUI [1,3]
C0332307
UMLS CUI [2,1]
C2347026
UMLS CUI [2,2]
C0007634
UMLS CUI [2,3]
C0449560
UMLS CUI [3,1]
C1292533
UMLS CUI [3,2]
C0332307
UMLS CUI [4,1]
C1292533
UMLS CUI [4,2]
C0449560
Name of the center which conducted sequencing [MAYO]
Beskrivning

SEQUENCING_CENTER

Datatyp

string

Alias
UMLS CUI [1,1]
C1301943
UMLS CUI [1,2]
C0565990
UMLS CUI [1,3]
C1561491
Body site where sample was collected [bone, Tissue]
Beskrivning

BODY_SITE_CATEGORY

Datatyp

string

Alias
UMLS CUI [1,1]
C0449705
Tillbaka till toppen

Similar models

Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.

5 Formulär
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    4. Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    5. Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
pht005602
C3846158 (UMLS CUI [1,1])
SAMPLE_ID
Item
De-identified sample ID
string
C4684638 (UMLS CUI [1,1])
C1299222 (UMLS CUI [1,2])
BODY_SITE
Item
Body site where sample was collected [Blood, bone, liver, lung, lymph node, Prostate Bed, Soft Tissue, supraclavicular aden
string
C0449705 (UMLS CUI [1,1])
ANALYTE_TYPE
Item
Analyte type [DNA, RNA]
string
C4744818 (UMLS CUI [1,1])
IS_TUMOR
Item
Tumor status [metastatic tumor, normal]
string
C0475752 (UMLS CUI [1,1])
PRIMARY_METASTATIC_TUMOR
Item
Primary metastatic tumor
text
C0677930 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
PRIMARY_TUMOR_LOCATION
Item
Primary tumor location
text
C0475447 (UMLS CUI [1,1])
Stage
Item
Stage
text
C1300072 (UMLS CUI [1,1])
TUMOR_TREATMENT
Item
Tumor treatment
text
C0087111 (UMLS CUI [1,1])
C0027651 (UMLS CUI [1,2])
TREATMENT_POST_VISIT
Item
Treatment post visit
text
C0087111 (UMLS CUI [1,1])
C0231290 (UMLS CUI [1,2])
C0545082 (UMLS CUI [1,3])
HISTOLOGICAL_TYPE
Item
Cell or tissue type or subtype of sample
string
C2347026 (UMLS CUI [1,1])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
SEQUENCING_CENTER
Item
Name of the center which conducted sequencing [MAYO]
string
C1301943 (UMLS CUI [1,1])
C0565990 (UMLS CUI [1,2])
C1561491 (UMLS CUI [1,3])
BODY_SITE_CATEGORY
Item
Body site where sample was collected [bone, Tissue]
string
C0449705 (UMLS CUI [1,1])
Tillbaka till toppen